Disc Medicine Reports Strong Q1 Clinical Progress and $730M Cash Position, Extending Runway into 2029

summarizeSummary

Disc Medicine announced strong Q1 2026 results, including the completion of Phase 3 enrollment for bitopertin, upcoming oral presentation of DISC-0974 data at ASCO, and a robust cash position of $730.2 million extending its operational runway into 2029.

check_boxKey Events

• Strong Financial Position

  Cash, cash equivalents, and marketable securities totaled $730.2 million as of March 31, 2026, which is expected to fund operational plans into 2029.

• Bitopertin Phase 3 Enrollment Complete

  Enrollment for the Phase 3 APOLLO clinical trial of bitopertin in erythropoietic protoporphyria (EPP) has been completed, with topline data anticipated in Q4 2026. A Type A meeting with the US FDA is scheduled for Q2 2026 to review the approach for resubmission following the previous Complete Response Letter, with an FDA decision expected by mid-2027.

• DISC-0974 Data Presentation at ASCO

  Updated data from the Phase 2 RALLY-MF trial of DISC-0974 in patients with anemia of myelofibrosis (MF) will be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in June, covering 61 patients. Topline data from the RALLY-MF study is also expected in Q4 2026.

• Pipeline Advancement with Q4 Data Expected

  Progress continues for the ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and the Phase 1b study of DISC-3405 in sickle cell disease (SCD), with initial data from both studies expected in Q4 2026.

auto_awesomeAnalysis

Disc Medicine's first-quarter report highlights significant clinical advancements and a robust financial position, which are critical for a clinical-stage biopharmaceutical company. The completion of Phase 3 enrollment for bitopertin and the upcoming oral presentation of DISC-0974 data at ASCO are major catalysts that could drive investor interest and validate the company's pipeline. The substantial cash runway into 2029 provides financial stability, mitigating near-term funding concerns despite increased operating expenses as programs advance. Investors should monitor the upcoming data readouts in Q4 2026 and the progress with the FDA regarding bitopertin's resubmission.